AOD9604 is a specialized peptide developed from a fragment of human growth hormone (hGH). Originally designed to support fat burning, it is now also valued for its promising properties in other areas. Studies suggest that AOD9604 may promote the breakdown of fat and reduce the formation of new fat cells. In addition, there is evidence of positive effects on cardiovascular diseases, joint problems such as osteoarthritis, and metabolism.

BPC-157 is a pentadecapeptide consisting of 15 amino acids. It is a partial sequence of the so-called Body Protection Compound (BPC), which was originally discovered and isolated in human gastric juice. Animal studies suggest that BPC-157 may accelerate the healing of various injuries, including those affecting muscles, tendons, and damaged ligaments. In addition, it helps protect organs and contributes to the prevention of gastric ulcers. Within the digestive tract, BPC-157 acts systemically and may relieve conditions such as leaky gut, irritable bowel syndrome, gastrointestinal cramps, and Crohn’s disease. Analgesic (pain-relieving) properties have also been attributed to this peptide. Research further indicates that BPC-157 may speed up the healing of skin burns by improving blood flow to damaged tissues. Moreover, it supports reticulin and collagen formation, promotes angiogenesis, and stimulates the activity of macrophages and fibroblasts — making BPC-157 a promising candidate in wound-healing therapy.

Diese Kombination aus BPC-157 und TB-500 vereint zwei der bekanntesten Peptide zur Unterstützung von Heilungs- und Regenerationsprozessen. BPC-157 kann die Regeneration von Muskeln, Sehnen, Bändern und Magen-Darm-Gewebe fördern, während TB-500 das Wachstum neuer Blutgefäße unterstützt, Entzündungen reduziert und die Gewebereparatur beschleunigt. Gemeinsam können diese Peptide synergistisch wirken, um Heilungsprozesse zu optimieren, die Erholungszeit nach Verletzungen zu verkürzen und die allgemeine Gewebegesundheit zu verbessern. Unsere Peptide werden in lyophilisierter Pulverform geliefert, um eine maximale Stabilität, Reinheit und Haltbarkeit zu gewährleisten. Durch die Gefriertrocknung bleibt die molekulare Struktur optimal erhalten, sodass die Substanz auch bei längerer Lagerung ihre Qualität behält.

CJC-1295 DAC, also known as Modified GRF (modGRF), is a shortened peptide analogue of growth hormone–releasing hormone (GHRH). It was first developed in the 1980s. Research suggests that modGRF may support muscle repair and growth, accelerate wound healing, strengthen bone health, enhance fat metabolism, and improve overall metabolic function. There is also evidence indicating beneficial effects on blood sugar regulation and immune system support.

Unsere Peptide werden in lyophilisierter Pulverform geliefert, um eine maximale Stabilität, Reinheit und Haltbarkeit zu gewährleisten. Durch die Gefriertrocknung bleibt die molekulare Struktur optimal erhalten, sodass die Substanz auch bei längerer Lagerung ihre Qualität behält.

The hGH Fragment 176-191 is a small synthetic segment of natural human growth hormone (hGH). Because of its fat-burning properties, it is often referred to as the “lipolytic fragment.” Studies suggest that it may help lower blood glucose levels and support cartilage healing — without stimulating long bone growth, increasing IGF-1 levels, or altering insulin sensitivity.

Ipamorelin is a short peptide sequence that binds to the ghrelin/growth hormone secretagogue receptor. It is considered one of the most selective growth hormone secretagogues known. Laboratory studies show that Ipamorelin does not affect ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release. Because of its high selectivity, Ipamorelin is of interest both as a potential therapeutic option and as a model peptide for studying receptor selectivity in GH binding. It plays an important role in growth and in the regeneration of muscle and skeletal tissue.

Triple Agonist Peptide for Advanced Metabolic Research Retatrutide is an innovative, multifunctional research peptide acting as a triple agonist on three key metabolic receptors: the GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and Glucagon Receptor (GCGR). This unique receptor combination makes Retatrutide one of the most exciting compounds in modern metabolic and endocrine research. Retatrutide – Properties, Mechanism of Action & Scientific Data As the first compound featuring a triple-receptor agonism, Retatrutide has demonstrated remarkable potential in Phase II clinical studies (New England Journal of Medicine 2023, Lancet 2023): Up to 24.2 % body-weight reduction after 48 weeks 83 % of participants lost ≥ 15 % of their body weight HbA1c improvement by up to –2.02 % Liver-fat reduction by up to 82 % Triglyceride reduction (–35 %) and non-HDL cholesterol (–20 %) These findings indicate that Retatrutide simultaneously enhances energy expenditure, stimulates fat oxidation, and promotes balanced glucose and lipid metabolism. Mechanistic Insights GLP-1 Receptor: Activates hypothalamic satiety pathways, reduces food intake, delays gastric emptying and stimulates insulin secretion. GIP Receptor: Promotes glucose-dependent insulin release without hypoglycemia risk; triggers “browning” of white adipose tissue → higher energy output. Glucagon Receptor (GCGR): Suppresses hepatic gluconeogenesis, enhances lipolysis and fatty-acid oxidation → reduced body fat and improved glycemic stability. Moreover, Retatrutide has been shown to decrease expression of the ANGPTL3/8 complex – a natural inhibitor of lipoprotein lipase – thus supporting lipid clearance and improving cardiometabolic profiles. Retatrutide in Liver and Diabetes Research Retatrutide shows promising effects in studies on Type 2 Diabetes and non-alcoholic fatty liver disease (NAFLD / NASH): Improved liver parameters via suppression of inflammatory cytokines (TNF-α, IL-6) Activation of PPAR signaling → enhanced β-oxidation and hepatic fat catabolism Increased insulin sensitivity through Akt pathway activation Anti-inflammatory modulation of Kupffer cells → reduced hepatic inflammation and fibrosis risk Molecular Data CAS Number: 2381089-83-2 PubChem CID: 171390338 Molecular Formula: C221H342N46O68 Molecular Weight: 4731 g/mol Synonym: GTPL-13769 Sequence: His-d-2Nal-Asp-Phe-Ile-His-Trp-Lys-Thr-Asp-Phe-Ser-Arg-Tyr-Arg-Lys-Val-Leu-Gly-Gly-Ala-Arg-Ala-Arg-Leu-Leu-Glu-His-Ser-Glu-Gln-Lys-Lys-His-Asn-Phe-Val-Gly-Trp-Met-Asp-Arg-Phe-Phe-Tyr-Pro-Arg-Lys-Thr-Pro-Gly-Thr-Ser-Phe-Tyr-Pro-Glu-Thr-Phe-Thr-Phe-Lys-Asn-Leu-Glu-Trp-Leu-Lys-His-Ser-Asn-Leu-Asn-Ser Formulation & Quality Ultimate Biolabs provides Retatrutide as a lyophilized (powder) form to ensure maximum stability, purity and shelf life. Freeze-drying preserves molecular integrity so the compound maintains its quality even during extended storage. Each batch is produced under laboratory conditions and undergoes rigorous quality control. Intended Use Retatrutide 30 mg is intended for research and in vitro use only – not for human or animal consumption. Ideal for scientific studies in: Peptide and metabolic research Endocrinology and diabetes modeling Obesity and energy metabolism analysis Liver and cell metabolism research ⚠️ For Research Use Only – Not for human or animal consumption.

Tesamorelin is a synthetic peptide consisting of 44 amino acids. It is an analogue of growth hormone–releasing hormone (GHRH) and has been primarily studied in the context of treating HIV-associated lipodystrophy (abnormal and toxic fat accumulation). In addition, Tesamorelin is being investigated for its potential to support peripheral nerve health, slow the progression of mild cognitive impairment, and reduce visceral fat. Clinical studies show that Tesamorelin can reduce fat mass in this patient group by nearly 20%. It is also believed to be up to four times more effective in reducing obesity than all other available therapies combined.